Abbott Laboratories 2012 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

A Productive Pipeline
AbbVie’s future success will grow from the output of
the company’s new-product pipeline. AbbVie research
programs include a strategic mix of biologic and small-
molecule therapies, and are focused in areas of signicant
unmet medical need.
Over the next several years, AbbVie hopes to launch
numerous medicines currently in mid- to late-stage
development that have truly breakthrough potential,
including several that represent billion-dollar-plus peak-
sales opportunities.
AbbVie is making signicant clinical progress in its
mission to create a treatment for Hepatitis C virus (HCV)
infection. HCV aects 170 million people worldwide,
and can potentially lead to long-term complications,
including severe scarring of the liver, liver cancer or death.
AbbVie is developing a treatment for HCV infection that
is currently in Phase Three trials, with commercialization
targeted for 2015. AbbVie’s treatment has shown
the potential to be potent, well-tolerated and easy to
administer, and to deliver very high cure rates, without the
use of interferon. AbbVie has the potential to achieve a
strong leadership position in this space.
Other pipeline programs in Phase Three or submitted for
regulatory approval include:
• Four new
Humira
indications, several of which will
be unique to
Humira
, helping to further dierentiate
this important drug from its competition;
• Daclizumab, a next-generation biologic in development
with Biogen IDEC for relapsing remitting multiple
sclerosis;
• Elagolix, a compound for endometriosis and uterine
broids that has the potential to provide symptom
reduction while avoiding signicant bone loss or
other adverse eects that can sometimes be associated
with current treatments;
•
Duopa
, a therapy for advanced Parkinson’s disease;
• Elotuzumab, a biologic treatment for multiple
myeloma being developed in partnership with
Bristol-Myers Squibb.
AbbVie’s mid-stage pipeline has 10 active programs,
several with strong proof-of-concept data. Highlights
include ve promising assets poised to advance into
Phase Three:
• Two promising oncology compounds: a next-generation
Bcl-2 inhibitor that has shown strong activity in
hematologic malignancies and a PARP inhibitor that has
demonstrated activity in BRCA-decient breast and
other cancers.
• A novel investigational compound for the prevention
of acute kidney injury associated with major surgery,
• A compound to treat diabetic nephropathy,
the damage to the kidneys oen experienced by
people with diabetes.
• A novel compound that has shown promise against
Alzheimer’s disease and cognitive impairment
associated with schizophrenia.
Humira: #1 global anti-TNF / Strong, Sustainable Growth Driver
#1
global anti-
TNF, growing
double-digits
10
years on
the market
15
years of
clinical data
9
approved
indications
4
new indications
in late-stage
development
670,000
patients
worldwide
Abbott 2012 Annual Report
21